Another explanation for the significant differences in the HRAS gene expression level but not KRAS in NSCLC patients, seems the fact that oncogenic alterations in KRAS are more frequent in patients with lung malignancies [21]. The gene discussed is HRAS; the disease is non-small cell lung carcinoma.